ysk05 has been researched along with 1-2-dioleoyloxy-3-(trimethylammonium)propane* in 1 studies
1 other study(ies) available for ysk05 and 1-2-dioleoyloxy-3-(trimethylammonium)propane
| Article | Year |
|---|---|
A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Hepatocellular carcinoma (HCC), a common deadly malignancy, requires novel therapeutic strategies to improve the survival rate. Combining chemotherapy and gene therapy is a promising approach for increasing efficiency and reducing side effects. We report on the design of highly specific lipid nanoparticles (LNPs) encapsulating both the chemotherapeutic drug, sorafenib (SOR), and siRNA against the midkine gene (MK), thereby conferring a novel highly efficient anticancer effect on HCC. The LNPs were modified with a targeting peptide, SP94, which is selective for hepatic cancer cells (HCCs), thus permitting the specific delivery of the payload. MK-siRNA increased the sensitivity of HCCs, HepG2, to SOR (IC Topics: Carcinoma, Hepatocellular; Cell Survival; Combined Modality Therapy; Drug Delivery Systems; Drug Liberation; Drug Synergism; Fatty Acids, Monounsaturated; Gene Knockdown Techniques; Gene Silencing; Genetic Therapy; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Midkine; Nanoparticles; Piperidines; Quaternary Ammonium Compounds; RNA, Small Interfering; Sorafenib | 2019 |